Trials / Completed
CompletedNCT01570959
Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Steady State Fasted Conditions
A Two Period, Two Treatment, Two Way, Steady State Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Fasting Conditions
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Roxane Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Quetiapine Fumarate 300 mg Tablet under fasted steady state conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Quetiapine Fumarate | 300 mg tablet |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2007-11-01
- Completion
- 2007-11-01
- First posted
- 2012-04-04
- Last updated
- 2018-01-23
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01570959. Inclusion in this directory is not an endorsement.